Full Press Release Details
Pro Forma Balance Sheet
| October 31, 2023 (Unaudited) | September 30, 2023 (Unaudited) | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 2,283,403 | $ | 186,401 | ||||
| Accounts receivable, net | 189,279 | 567,510 | ||||||
| Inventories, net | 1,009,410 | 965,091 | ||||||
| Research and development tax incentive receivable | 551,261 | 559,588 | ||||||
| Other current assets | 303,322 | 413,305 | ||||||
| Total current assets | 4,336,675 | 2,691,895 | ||||||
| Property and equipment, net | 553,642 | 664,922 | ||||||
| Operating lease right-of-use assets | 464,071 | 471,532 | ||||||
| Intangible assets, net | 4,770,470 | 4,872,141 | ||||||
| TOTAL ASSETS | $ | 10,124,858 | $ | 8,700,490 | ||||
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable and accrued expenses | $ | 2,078,866 | $ | 3,628,797 | ||||
| Current portion of operating lease liabilities | 222,652 | 227,414 | ||||||
| Current portion of deferred grant income | 2,299,900 | 2,240,929 | ||||||
| Current employee benefit liabilities | 352,445 | 406,964 | ||||||
| Current portion of notes payable | 352,389 | 341,834 | ||||||
| Total current liabilities | 5,306,252 | 6,845,938 | ||||||
| Employee benefit liabilities, less current portion | 27,251 | 27,732 | ||||||
| Operating lease liabilities, less current portion | 281,421 | 284,028 | ||||||
| Notes payable, less current portion | 269,305 | 306,234 | ||||||
| Total liabilities | 5,884,229 | 7,463,932 | ||||||
| Commitments and contingencies | ||||||||
| Shareholders' equity: | ||||||||
| Common stock, $0.01 par value, 100,000,000 shares authorized, 8,734,381, 2,330,399 shares issued and outstanding as of October 31, 2023 and September 30, 2023, respectively | 87,344 | 23,304 | ||||||
| Treasury stock, at cost, 1,386 shares as of October 31, 2023, and September 30, 2023, respectively | (14 | ) | (14 | ) | ||||
| Series E preferred stock, $0.01 par value, 10,000,000 shares authorized, 1,556,962 and shares issued and outstanding as of October 31, 2023 and September 30, 2023 respectively | 15,569 | - | ||||||
| Additional paid-in capital | 49,865,318 | 46,158,763 | ||||||
| Accumulated deficit | (45,013,301 | ) | (44,232,777 | ) | ||||
| Accumulated other comprehensive loss | (592,708 | ) | (593,512 | ) | ||||
| Total consolidated Intelligent Bio Solutions Inc. equity | 4,362,208 | 1,355,764 | ||||||
| Non-controlling interest | (121,579 | ) | (119,206 | ) | ||||
| Total shareholders' equity | 4,240,629 | 1,236,558 | ||||||
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $ | 10,124,858 | $ | 8,700,490 |